Stichting Tuberculosis Vaccine Initiative, operating under the name Tbvi, is located in null. The organization was established in 2009. According to its NTEE Classification (H12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Tbvi is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Tbvi generated $1.4m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 7 years, the organization has seen revenues fall by an average of (6.0%) each year. All expenses for the organization totaled $1.4m during the year ending 12/2021. As we would expect to see with falling revenues, expenses have declined by (6.2%) per year over the past 7 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
TO SUPPORT INTEGRATE TRANSLATE AND PRIORITISE R&D EFFORTS TO DISCOVER AND DEVELOP NEW TUBERCULOSIS VACCINES THAT ARE ACCESSIBLE AND AFFORDABLE FOR ALL.
Describe the Organization's Program Activity:
Part 3 - Line 4a
TBVI MOBILISES RESOURCES AND IDENTIFIES DEVELOPS AND MANAGES PROJECTS FOR TB VACCINE R&D WITH A PARTICULAR FOCUS ON DISCOVERY PRECLINICAL AND EARLY CLINICAL ACTIVITIES. IN ADDITION IT SUPPORTS PROJECTS FOR THE DISCOVERY OPTIMISATION AND VALIDATION OF BIOMARKERS. TBVI WORKS WITH GOVERNMENTS FOUNDATIONS AND THE PRIVATE SECTOR TO INCREASE PUBLIC FUNDING AS WELL AS PRIVATE SECTOR INVESTMENT OPPORTUNITIES FOR R&D OF NEW VACCINES.
TBVI BRINGS TOGETHER THE EFFORTS OF LEADING UNIVERSITIES GOVERNMENT INSTITUTES BIOTECH AND VACCINE COMPANIES THROUGH TB VACCINE AND BIOMARKER DISCOVERY AND DEVELOPMENT PROJECTS. TBVI CREATES AN ENABLING ENVIRONMENT THROUGH ITS KNOWLEDGE-SHARING PLATFORM INCLUDING MEETINGS SYMPOSIA AND WORKSHOPS AND THROUGH JOINT COLLABORATIVE RESEARCH THAT STIMULATES KNOWLEDGE EXCHANGE AND CREATES SYNERGIES AMONG R&D PARTNERS AND OTHER STAKEHOLDERS IN THE FIELD.
TBVI SUPPORTS TRANSLATION FROM IDEAS TO TANGIBLE PRODUCTS THROUGH THE ADVISORY SERVICES OF ITS PRODUCT & CLINICAL DEVELOPMENT TEAM P&CDT. THIS TEAM OF INDEPENDENT VACCINE R&D EXPERTS SUPPORTS TBVI'S R&D PARTNERS IN MOVING THEIR CANDIDATES FROM DISCOVERY TO EARLY CLINICAL DEVELOPMENT. IN ITS STRATEGY TBVI CONSIDERS THE NEED TO: DISCOVER AND DEVELOP SAFE AND EFFECTIVE VACCINES FOR ALL; PREVENT INFECTION AND TRANSMISSION OF DISEASE; BUILD ON THE R&D COMPARATIVE ADVANTAGE OF THE TBVI CONSORTIUM MEMBERS; MAKE THE BEST USE OF LIMITED RESOURCES AND MOBILISE ADDITIONAL FUNDING.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Meinema Dir Finance And Adminsitration | Officer | 40 | $75,240 |
Holleman Knowledge Exchange And Networking M | Officer | 32 | $55,874 |
Agterdenbosch Sr Management Assistent | Officer | 36 | $39,233 |
DE Lange General Legal Counsel | Officer | 10 | $17,309 |
Roozendaal Director External Relations And Res | Officer | 20 | $16,743 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $760,449 |
All other contributions, gifts, grants, and similar amounts not included above | $601,137 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $1,361,586 |
Total Program Service Revenue | $0 |
Investment income | $0 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $1,394,481 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $258,482 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $542,121 |
Compensation of current officers, directors, key employees. | $22,800 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $0 |
Pension plan accruals and contributions | $88,058 |
Other employee benefits | $0 |
Payroll taxes | $60,512 |
Fees for services: Management | $136,823 |
Fees for services: Legal | $0 |
Fees for services: Accounting | $0 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $175,668 |
Advertising and promotion | $0 |
Office expenses | $76,367 |
Information technology | $0 |
Royalties | $0 |
Occupancy | $0 |
Travel | $440 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $4,504 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $820 |
Insurance | $0 |
All other expenses | $17,793 |
Total functional expenses | $1,361,588 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $2,681,551 |
Savings and temporary cash investments | $0 |
Pledges and grants receivable | $11,069 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $0 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $0 |
Total assets | $2,692,620 |
Accounts payable and accrued expenses | $24,403 |
Grants payable | $2,595,219 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $2,619,622 |
Net assets without donor restrictions | $0 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $72,998 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $2,692,620 |
Organization Name | Assets | Revenue |
---|---|---|
Joseph Rowntree Foundation | $422,657,604 | $8,163,690 |
American School Of Milan | $34,975,339 | $18,900,429 |
Shalva Israel Assoc To Relieve The Handicapped Child And Family | $89,694,654 | $19,416,096 |
Cuso International | $17,986,190 | $25,338,532 |
West Africa Rice Development Association | $23,999,248 | $19,439,683 |
Merton College | $449,219,486 | $18,363,821 |
Cooperativa De Ahorro Y Credito De Vega Alta | $355,977,126 | $21,743,565 |
Ivey Business School Foundation | $20,172,840 | $19,210,645 |
Tula Foundation | $43,438,708 | $5,288,962 |
Allgemeine Anthroposophische | $21,895,649 | $16,689,603 |
Master & Fellows Of Peterhouse | $470,069,266 | $14,639,374 |
Bermuda Institute Of Ocean Sciences Bios Inc | $48,144,596 | $11,893,948 |